Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

1.8K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
1.8K
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

578
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
578
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

1.3K
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
1.3K
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

1.0K
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.0K
Peptic Ulcer Disease II: Pathophysiology01:28

Peptic Ulcer Disease II: Pathophysiology

2.4K
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
2.4K
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies01:28

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

722
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
722

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

"Once in a lifetime is enough": a patient viewpoint of toxic epidermal necrolysis.

Clinical and experimental dermatology·2026
Same author

A waxy wonder: unveiling a rare dermatological mystery.

Skin health and disease·2026
Same author

Frailty in hidradenitis suppurativa: a case-control study.

Clinical and experimental dermatology·2025
Same author

'I'm definitely more confident now': a qualitative study exploring how GP trainees learn about dermatology.

Skin health and disease·2025
Same author

When Classic Signs Deceive: A Widespread Papulosquamous Eruption in Skin of Colour.

Dermatopathology (Basel, Switzerland)·2025
Same author

The diagnosis of early-stage mycosis fungoides: Views held by experts and non-experts in cutaneous lymphoma.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·2025

Related Experiment Video

Updated: Mar 6, 2026

Effects of Taste Signaling Protein Abolishment on Gut Inflammation in an Inflammatory Bowel Disease Mouse Model
09:31

Effects of Taste Signaling Protein Abolishment on Gut Inflammation in an Inflammatory Bowel Disease Mouse Model

Published on: November 9, 2018

9.2K

Oral Sweet's syndrome occurring in ulcerative colitis.

Laura Aisling Nestor1, Anne-Marie Tobin1

  • 1Department of Dermatology, Adelaide and Meath Hospital, Tallaght, Ireland.

BMJ Case Reports
|March 17, 2017
PubMed
Summary

A 78-year-old man with ulcerative colitis developed painful mouth ulcers and skin nodules. Treatment with prednisolone and colchicine successfully resolved these symptoms, indicating oral Sweet's syndrome.

Area of Science:

  • Dermatology
  • Gastroenterology
  • Rheumatology

Background:

  • A 78-year-old male with a history of ulcerative colitis, managed with adalimumab, presented with symptoms suggestive of an inflammatory condition.
  • Ulcerative colitis is a chronic inflammatory bowel disease that can have extraintestinal manifestations.

Observation:

  • The patient reported a 3-week history of tender mouth ulceration, arthralgia, and weight loss.
  • Clinical examination revealed severe oral ulceration and tender erythematous nodules on the forehead.
  • Laboratory tests showed elevated C-reactive protein (CRP) and neutrophilia.

Findings:

  • Histopathological examination of a punch biopsy demonstrated dermal edema and a neutrophil-rich inflammatory infiltrate.
  • The clinical presentation and biopsy findings led to a working diagnosis of oral Sweet's syndrome.

More Related Videos

Author Spotlight: Oral Candida Diagnosis to Advance Clinical Treatment Regimen for pSS Patients
05:26

Author Spotlight: Oral Candida Diagnosis to Advance Clinical Treatment Regimen for pSS Patients

Published on: March 1, 2024

2.1K
Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model
09:11

Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model

Published on: February 14, 2021

10.7K

Related Experiment Videos

Last Updated: Mar 6, 2026

Effects of Taste Signaling Protein Abolishment on Gut Inflammation in an Inflammatory Bowel Disease Mouse Model
09:31

Effects of Taste Signaling Protein Abolishment on Gut Inflammation in an Inflammatory Bowel Disease Mouse Model

Published on: November 9, 2018

9.2K
Author Spotlight: Oral Candida Diagnosis to Advance Clinical Treatment Regimen for pSS Patients
05:26

Author Spotlight: Oral Candida Diagnosis to Advance Clinical Treatment Regimen for pSS Patients

Published on: March 1, 2024

2.1K
Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model
09:11

Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model

Published on: February 14, 2021

10.7K
  • The patient's symptoms resolved completely following treatment with oral prednisolone and colchicine.

    • Implications:

    • This case highlights the importance of considering Sweet's syndrome in patients with inflammatory bowel disease presenting with oral and cutaneous lesions.
    • Early diagnosis and appropriate management, including corticosteroids and colchicine, can lead to favorable outcomes.
    • The successful treatment underscores the efficacy of targeted therapies for managing complex inflammatory presentations in patients with pre-existing autoimmune conditions.